Who is Hugh Auchincloss? Anthony Fauci asked deputy about 'ties' to Covid-19 outbreak in China
Social media was flooded with email from Anthony Fauci's inbox and people are asking about 'tasks' that Hugh Auchincloss was asked to carry out
Bombshell emails from Dr Anthony Fauci's inbox suggest that the director of the US National Institute of Allergy and Infectious Diseases (NIAID) was worried that his organization might have ties to the Covid-19 outbreak in China.
Social media was flooded with emails recovered from Fauci's inbox after they were obtained by the Washington Post and Buzzfeed News via a Freedom of Information Act. In one email to NIAID Principal Deputy Director Hugh Auchincloss on February 1, 2020, Fauci expressed a sense of urgency and alarm over a research. The subject line was "IMPORTANT" as Fauci attached a 2015 paper from Nature Medicine describing gain-of-function research on coronaviruses that the director of the Wuhan Institute of Virology had helped conduct and that numerous scientists had criticized as risky.
"Hugh, it is essential that we speak this AM," Fauci wrote. "Read this paper... You will have tasks today that must be done," he added, although it is unclear what "tasks" he was referring to.
2/ But Dr. Fauci had other calls on his mind that day too.— Alex Berenson (@AlexBerenson) June 2, 2021
At 12:29 a.m. on Feb. 1 (a Saturday), he emailed his deputy, Dr. Hugh Auchincloss. The subject line was "IMPORTANT." He attached a 2015 paper from Nature Medicine describing gain-of-function research on coronaviruses...
4/ Tasks that must be done. Gee, that doesn't sound suspicious at all.— Alex Berenson (@AlexBerenson) June 2, 2021
What tasks? I dunno, Dr. Fauci didn't say specifically - at least not in any emails we've seen yet. Maybe he just was sending ol' Hugh on a coffee run. Mocha, skim, hop to it, doc!
Or maybe not.
FAUCIGATE:rotating_light:— 404_Not_Found (@4_04_Not_Found) June 2, 2021
An email from Dr. Fauci to Hugh Auchincloss, the NIAID Deputy Director on Feb 1, 2020.
Attachments: Baric, Shi et al - Nature Medicine - SARS Gain of function.pdf pic.twitter.com/Drz3rS8NUM
Meanwhile, Auchincloss' response also managed to raise some eyebrows. “The paper you sent me says the experiments were performed before the gain of function pause but have since been reviewed and approved by NIH," he wrote. "Not sure what this means since Emily is sure that no Coronavirus work has gone through the P3 framework. She will try to determine if we have any distant ties to this work abroad.”
In March, there was a Nature Medicine article that netizens were circulating as proof that Covid-19 could have come from a lab. However, Nature editors have now been accused of adding an update saying there's no evidence that the virus came from a lab, and that “scientists believe that an animal is the most likely source of the coronavirus.”
According to Arkansas Senator Tom Cotton, however, Dr Anthony Fauci has got some answering to do.
Fauci has some questions to answer.— Tom Cotton (@TomCottonAR) June 2, 2021
Who is Hugh Auchincloss?
As NIAID's principal deputy director, Hugh Auchincloss, MD, is responsible for providing leadership to all NIAID research planning and implementation activities, including "helping to prepare and support a strategic vision for NIAID" as well as "overseeing an extensive portfolio of basic, clinical, and applied research, as well as product development for biodefense, HIV/AIDS, infectious diseases, and immune-mediated disorders," per the NIAID website.
Recently, Auchincloss has been focused on spearheading the development of the NIH's strategic plan and chairing the NIAID Research Initiative Committee, which helps develop more efficient approaches to "planning, developing, and approving NIAID initiatives." Auchincloss is currently leading an NIAID initiative to upgrade the Institute’s clinical research infrastructure in order to accommodate clinical research on HIV/AIDS and other infectious diseases.
Furthermore, Auchincloss is also responsible for reviewing all aspects of HIV/AIDS research policy, including "the evaluation of 'test and treat' strategies, analysis of results of pre-exposure prophylaxis (PrEP) clinical trials (including microbicide trials), and coordination of future HIV/AIDS vaccine clinical trials."